COMPASS PATHW SP.ADR (5Y6) - Total Liabilities
Based on the latest financial reports, COMPASS PATHW SP.ADR (5Y6) has total liabilities worth €263.20 Million EUR (≈ $307.70 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore 5Y6 shareholders equity momentum to track the company's year-over-year net asset growth rate.
COMPASS PATHW SP.ADR - Total Liabilities Trend (2021–2025)
This chart illustrates how COMPASS PATHW SP.ADR's total liabilities have evolved over time, based on quarterly financial data.
COMPASS PATHW SP.ADR Competitors by Total Liabilities
The table below lists competitors of COMPASS PATHW SP.ADR ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
AGF Management Limited
F:A3J
|
Germany | €504.67 Million |
|
VGI Public Company Limited
BK:VGI
|
Thailand | ฿3.49 Billion |
|
Kempower Oyj
HE:KEMPOWR
|
Finland | €144.90 Million |
|
J Resources Asia Pasifik Tbk
JK:PSAB
|
Indonesia | Rp257.62 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$454.35 Million |
|
Shinyoung HappyTomorrow No.5 Special Purpose Acquisition Company
KQ:323280
|
Korea | ₩65.35 Billion |
|
Zhejiang Dehong Automotive
SHG:603701
|
China | CN¥850.52 Million |
|
Evergent Investments SA
RO:EVER
|
Romania | RON637.62 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down COMPASS PATHW SP.ADR's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 5Y6 stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.77 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -4.98 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how COMPASS PATHW SP.ADR's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for COMPASS PATHW SP.ADR (2021–2025)
The table below shows the annual total liabilities of COMPASS PATHW SP.ADR from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €263.20 Million ≈ $307.70 Million |
+346.32% |
| 2024-12-31 | €58.97 Million ≈ $68.94 Million |
+17.37% |
| 2023-12-31 | €50.24 Million ≈ $58.74 Million |
+213.74% |
| 2022-12-31 | €16.01 Million ≈ $18.72 Million |
-2.86% |
| 2021-12-31 | €16.49 Million ≈ $19.27 Million |
-- |
About COMPASS PATHW SP.ADR
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as … Read more